These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15342238)

  • 1. Regulation of DNA binding of p53 by its C-terminal domain.
    Weinberg RL; Freund SM; Veprintsev DB; Bycroft M; Fersht AR
    J Mol Biol; 2004 Sep; 342(3):801-11. PubMed ID: 15342238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
    Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
    Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent and active p53 are identical in conformation.
    Ayed A; Mulder FA; Yi GS; Lu Y; Kay LE; Arrowsmith CH
    Nat Struct Biol; 2001 Sep; 8(9):756-60. PubMed ID: 11524676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMX inhibits the p300/CBP-mediated acetylation of p53.
    Sabbatini P; McCormick F
    DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitination of p53 at multiple sites in the DNA-binding domain.
    Chan WM; Mak MC; Fung TK; Lau A; Siu WY; Poon RY
    Mol Cancer Res; 2006 Jan; 4(1):15-25. PubMed ID: 16446403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C terminus of p53 binds the N-terminal domain of MDM2.
    Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
    Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization.
    Sun XZ; Vinci C; Makmura L; Han S; Tran D; Nguyen J; Hamann M; Grazziani S; Sheppard S; Gutova M; Zhou F; Thomas J; Momand J
    Antioxid Redox Signal; 2003 Oct; 5(5):655-65. PubMed ID: 14580323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain.
    Pivonková H; Brázdová M; Kaspárková J; Brabec V; Fojta M
    Biochem Biophys Res Commun; 2006 Jan; 339(2):477-84. PubMed ID: 16300733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
    Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
    FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
    Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
    Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core.
    Zotchev SB; Protopopova M; Selivanova G
    Nucleic Acids Res; 2000 Oct; 28(20):4005-12. PubMed ID: 11024181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
    Craig AL; Burch L; Vojtesek B; Mikutowska J; Thompson A; Hupp TR
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):133-41. PubMed ID: 10432310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
    Dreyfus DH; Nagasawa M; Gelfand EW; Ghoda LY
    BMC Immunol; 2005 Jun; 6():12. PubMed ID: 15969767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
    Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
    J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
    [No Abstract]   [Full Text] [Related]  

  • 19. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain.
    Laptenko O; Shiff I; Freed-Pastor W; Zupnick A; Mattia M; Freulich E; Shamir I; Kadouri N; Kahan T; Manfredi J; Simon I; Prives C
    Mol Cell; 2015 Mar; 57(6):1034-1046. PubMed ID: 25794615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.